The v-mos gene of the Moloney murine sarcoma virus (MoMuSV) encodes a serine/threonine protein kinase (32) . Mutagenesis studies have shown that the protein kinase function of v-Mos correlates with its biological activity (55) . The cellular mos gene product (c-Mos) is required for the initiation of meiosis I and II and, as a part of the cytostatic factor, is also responsible for cell cycle arrest of the unfertilized egg at meiotic metaphase II (14, 25, 39, 41, 45, 46, 63) . Significantly, v-mos and c-mos gene products can substitute for each other in cellular transformation functions, induction of meiotic maturation, and cell cycle arrest (18) . This implies that both v-Mos and c-Mos are able to recognize the substrates that are relevant for cellular transformation as well for meiotic maturation. Furthermore, since both v-Mos and c-Mos colocalize with microtubules (7, 65) , they may be regulated by similar mechanisms.
Our previous studies have shown that phosphorylation plays an important role in the activation of v-Mos kinase (reviewed in reference 54). Specifically, the protein kinase C (PKC) pathway and p34 cdc2 kinase are involved in the activation of v-Mos kinase (2, 6, 28) . In the study reported here, we examined the role of cyclic AMP (cAMP)-dependent protein kinase (PKA) in the regulation of v-Mos protein kinase. This study was prompted by the observation in various laboratories that PKA plays a major inhibitory role in the initiation of oocyte maturation in both frogs and mice (8, 29, 47, 48, 60) . Here we report that an increase in PKA activity leads to inhibition of v-Mos kinase activity. Further studies involving in vitro phosphorylation of v-Mos by PKA and tryptic phosphopeptide analysis indicated that v-Mos kinase inhibition may be due to direct phosphorylation by PKA. This is the first report on the inhibition of v-Mos kinase by another protein kinase. Our results indicate that PKA may inhibit v-Mos via phosphorylation at the Ser-263 present in its substrate-binding domain.
MATERIALS AND METHODS
Cell lines and culture conditions. COS-1 cells were maintained in Dulbecco's modified Eagle's medium plus 10% fetal calf serum (FCS). NIH 3T3 cells were grown in Dulbecco's modified Eagle's medium plus 8% calf serum. The NRK6m2 cell line, which produces P85 gag-mos encoded by the ts110 mutant of MoMuSV (3) , was grown at 33ЊC in McCoy's 5A medium plus 12.5% FCS. At 50% confluency, the temperature was shifted to 30ЊC for 24 h to increase P85 gag-mos production. Sf9 insect cells (obtained from Invitrogen, San Diego, Calif.) were grown in modified Grace's insect cell culture medium plus 10% FCS at 28ЊC.
Plasmids and cell transfection. For expression in COS-1 cells, the v-mos gene and its mutants were expressed from the simian virus 40 late promoter by using the pJC119 vector as described previously (55) . The cDNA for the ␣ isoform of the mouse PKA catalytic subunit (PKA c ) cloned in MT-CEVneo (33) was obtained from Eric Olson at our institution. This expression vector contains the mouse metallothionein-1 promoter. Transfections were performed by the DEAE-dextran method as described previously (55) . For the stable transfection of v-mos expression vectors into NIH 3T3 cells, a neomycin expression vector, pKJ1 (1), was used for cotransfection and selection in the presence of geneticin (400 g/ml; GIBCO/BRL, Gaithersburg, Md.). In pKJ1, the neomycin gene is expressed by using the mouse phosphoglycerate kinase I promoter and polyadenylation signal.
Metabolic labeling and immunoprecipitation. For labeling with [ 35 S]methionine, COS-1 cells were incubated for 30 min in methionine-free Dulbecco's modified Eagle's medium and then for 1.5 h in methionine-free medium containing 10% dialyzed FCS and 0.2 mCi of trans-label (ICN, Costa Mesa, Calif.) per ml. Forskolin-treated cells were labeled in the presence of 100 M forskolin. For 32 P labeling, COS-1 cells were incubated for 1 h in phosphate-free Dulbecco's modified Eagle's medium containing 10% dialyzed FCS and 2 mCi of 32 P i per ml.
After being labeled, cells were washed with Tris-buffered saline three times and solubilized in 2 ml of extraction buffer containing phosphatase, kinase, and protease inhibitors as described previously (11, 24) . Cell extracts were centrifuged for 40 min at 40,000 ϫ g and 4ЊC to remove insoluble debris. They were then incubated with 30 l of normal rabbit serum for 15 min, and 30 l of protein A-Sepharose (50% suspension; Pharmacia, Piscataway, N.J.) was added for 15 min on ice. The beads were removed by microcentrifugation for 1 min at 4ЊC, and the supernatant fraction was incubated for 1 h with anti-Mos(37-55) or antiMos(260-271) antibodies and then with 50 l of protein A-Sepharose for 20 to 30 min on ice. The immunoprecipitates were collected by microcentrifugation for 1 min at 4ЊC and washed with extraction buffer three times. The precipitated proteins were analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) on a 10% polyacrylamide gel.
Protein kinase assays. The in vitro protein kinase assays with the v-Mos immune complexes precipitated with anti-Mos(37-55) antibodies were carried out as described previously (32, 56) . Transphosphorylation of glutathione-Stransferase (GST)-MEK1 (K97R) by v-Mos was carried out as described previously (42) . For MEK1 assays, the protein was immunoprecipitated with a monoclonal antibody (Transduction Laboratories, Lexington, Ky.). Autophosphorylation of MEK1 and phosphorylation of kinase-inactive mitogen-activated protein kinase (K52R) were carried under the same conditions as MEK1 phosphorylation by Mos. The relative amount of v-Mos was determined by Western immunoblotting as described previously (20) . In some experiments, enhanced chemiluminescence detection was carried out by using the reagents and protocol from Amersham. The specificity of Mos detection by the antipeptide antibodies was routinely determined with control peptide-blocked antibodies. The relative band intensities on the autoradiograms were determined by soft-laser densitometry.
Expression and purification of GST-v-Mos protein from Escherichia coli. The v-mos gene (1.16-kb XbaI-HindIII fragment) was digested with nuclease S1 to eliminate the termination codon upstream of the open reading frame and then cloned into the SmaI site of the bacterial expression vector pGEX-3X (Pharmacia) to yield pGEX-3X:mos. This construct encodes a glutathione-S-transferase (GST)-v-Mos fusion protein, which also includes two additional codons present upstream of the initiation codon of v-mos. The construct was transformed into E. coli JM109, and recombinant v-Mos protein was expressed and purified essentially as described previously (15) . Briefly, 100 ml of an overnight culture was diluted 1:10 in a final volume of 1,000 ml. After incubation for 1 h, isopropyl ␤-D-thiogalactoside (IPTG) was added to a final concentration of 0.1 mM and the cells were incubated for a further 3 h. Bacteria were harvested by centrifugation at 2,600 ϫ g for 20 min at 4ЊC. The pellets were then resuspended and lysed in 100 ml of STE (150 mM NaCl, 50 mM Tris-HCl [pH 7.2], 1 mM EDTA) containing 500 g of lysozyme per ml, 0.05% Nonidet P-40, 10 g of leupeptin per ml, 10 g of pepstatin A per ml, and 1 mM phenylmethylsulfonyl fluoride. After 10 min on ice, MgCl 2 and DNase A were added to final concentrations of 2.5 mM and 50 g/ml, respectively, and the mixture was incubated on ice for a further 30 min. The lysate was centrifuged at 17,000 ϫ g for 15 min at 4ЊC. The supernatant was incubated with 1 ml of 50% (vol/vol) glutathione-Sepharose 4B beads (Pharmacia) for 30 min at 4ЊC with gentle rocking. The beads were washed four times with 10 volumes of STE containing 10 g each of leupeptin and pepstatin A per ml and 1 mM phenylmethylsulfonyl fluoride.
Expression of recombinant p37 v-mos in insect cells. The 1.16-kb XbaI-HindIII fragment encompassing the entire v-mos gene of the myeloproliferative sarcoma virus (57) , blunt ended at the HindIII site, was cloned into XbaI-SmaI-digested baculovirus expression vector pVL-1392. The resultant plasmid, pVL-v-mos, and the linearized BaculoGold virus DNA (Pharmingen, San Diego, Calif.) were cotransfected into Sf9 insect cells. After 4 days, the supernatant fraction was collected and more cells were infected for amplification. After that, the plaque assay was performed to pick up a single plaque. This single plaque was suspended in 0.5 ml of insect cell medium, and the cells were infected with this medium for amplification. As a result, a high-titer stock solution (Ͼ10 8 PFU/ml) was obtained. To this end, freshly seeded insect cells were infected with the high-titer stock solution (9 ϫ 10 6 cells per T75 flask were incubated with 2 ml of the high-titer stock solution for 1 h). Then the cells were changed to fresh medium and were ready for harvesting after 40 h.
In vitro phosphorylation of v-Mos by PKA. For in vitro PKA phosphorylation reactions, 1 to 10 g of GST, GST-v-Mos, or immunoprecipitated recombinant baculovirus-expressed v-Mos was incubated with 10 U of the bovine heart PKA catalytic subunit (PKA c ) (Sigma Chemical Co., St. Louis, Mo.) at 30ЊC for 30 min in a total reaction volume of 30 l containing 40 mM Tris-HCl (pH 7.4), 20 mM magnesium acetate, 1 l of [␥-32 P]ATP (4,000 Ci/mmol; NEN), and 1 l of 1 mM ATP. For direct analysis of 32 P-labeled proteins, phosphorylation reactions were terminated by adding an equal volume of 2ϫ SDS sample buffer and samples were subsequently resolved by SDS-PAGE. Phosphorylation reactions of v-Mos protein immunoprecipitated from insect cells were carried out in a similar manner.
Synthetic peptides containing potential PKA phosphorylation sites were prepared in an automated peptide synthesizer in our synthetic antigen facility. The peptides were phosphorylated with PKA as described above for Mos phosphorylation. The phosphorylated peptides were separated from unincorporated [␥-32 P]ATP by ascending thin-layer chromatography on cellulose plates in phosphochromatography buffer (9) .
Phosphopeptide mapping analysis. For two-dimensional (2-D) peptide mapping, 32 P-labeled proteins were eluted from the excised gel pieces as described previously (9, 42) . The proteins were each mixed with 50 g of bovine serum albumin, precipitated with trichloroacetic acid, and oxidized with performic acid. After digestion with L-(tosylamido-2-phenyl)ethyl chloromethyl ketone (TPCK)-treated trypsin at 37ЊC for 18 h, the phosphopeptides were separated on cellulose plates (0.1 mm thick; Kodak, Rochester, N.Y.) as described previously (9) . In the first dimension, electrophoresis was carried out in a pH 2.1 buffer (water, 88% formic acid, acetic acid [90:2:8 by volume]) for 45 min at 1,000 V. In the second dimension, separation was carried out by ascending chromatography in a solvent containing N-butanol, acetic acid, water, and pyridine (75:15:60:50 by volume).
Site-directed mutagenesis. Alanine-for-serine substitution mutants were generated by double PCR with both sense and antisense oligonucleotides containing the mutations. The template for the mutagenesis studies was the v-mos gene surrounded by T3 and T7 promoters in pBluescript vector (Stratagene, La Jolla, Calif.). The mutations were confirmed by DNA sequencing, and the v-mos gene was recloned into expression vector pJC119 or pGEX-3X.
RESULTS

Inhibition of v-Mos kinase by PKA.
To examine the effect of PKA on v-Mos activity, we decided to increase the PKA activity in the cells by two different methods. First, we increased the cAMP level in cells by treatment with forskolin, a known activator of adenyl cyclase. In the second type of experiment, we overexpressed PKA c by transfection with a plasmid DNA into COS-1 cells. Figure 1 shows that the forskolin treatment of COS-1 cells expressing v-Mos caused a significant inhibition of v-Mos kinase that varied with the forskolin concentration and the time of treatment. The degree of v-Mos kinase inhibition increased with increases in forskolin concentration from 50 to 400 M (Fig. 1B) . Forskolin treatment did not affect the v-Mos protein level appreciably as analyzed by Western immunoblotting (Fig.  1C) . The slight decrease in the v-Mos level observed at the higher forskolin concentrations (200 to 400 M) was also insignificant compared with the nearly complete inhibition of the kinase activity (compare Fig. 1A , B, and C). Inhibition of v-Mos kinase by 100 M forskolin increased with time up to 120 min (Fig. 1A) . However, by 180 min, a good part of the inhibition was reversed. This result was reproducibly observed and may be due to attenuation or silencing of forskolin response by the cellular machinery, which operates at multiple levels (for a review, see reference 4). We also analyzed PKA activity (with a Pierce colorimetric PKA assay kit, Spinzyme format) from the cells treated with forskolin. Forskolin at 100 M caused a sharp increase in PKA activity within 30 min. It peaked at 90 min (reaching levels fivefold those of the control) and then declined, reaching close to basal level between 3 and 4 h (data not shown). The PKA activity also increased in a concentration-dependent manner in the 50 to 400 M range. Thus, there was a good correlation between PKA activation and Mos kinase inhibition. v-Mos kinase activity was analyzed by determining autophosphorylation in immune complexes as described previously (56) . Our previous studies have shown that the in vitro autophosphorylation activity of v-Mos kinase correlates with its ability to phosphorylate exogenous substrates, e.g., vimentin and MEK1 (51, 53; this study). More importantly, we have shown that v-Mos autophosphorylation sites are different from the sites of phosphorylation in vivo upon activation of PKA (see below).
v-Mos kinase activity was also inhibited upon cotransfection of the PKA c -encoding plasmid plus a v-Mos-encoding plasmid into COS-1 cells ( Fig. 2A) . Western immunoblotting analysis showed that the level of the v-Mos protein remained unchanged upon coexpression of PKA c (Fig. 2B) . Furthermore, forskolin treatment or PKA c coexpression did not affect the ability of v-Mos protein to be immunoprecipitated, as determined by [ v-mos produced in Sf9 insect cells with the baculovirus expression vector pVL-1392. Both proteins lacked protein kinase activity when assayed in vitro for autophosphorylation (62) or vimentin transphosphorylation activity (data not shown). This is presumably due to the lack of appropriate phosphorylation modifications. Thus, we were able to study phosphorylation of v-Mos by PKA in the absence of v-Mos autokinase activity. GST-Mos protein affinity purified by binding to GST-Sepharose was specifically phosphorylated by purified PKA c (Fig. 3A, lane 2) . As a control, purified GST protein was not phosphorylated (lane 3), indicating that the phosphorylation is restricted to the Mos domain within the GST-Mos fusion protein.
p37 v-mos encoded by the v-mos gene was produced in Sf9 insect cells in relatively large amounts. SDS-PAGE of total extracts from Sf9 cells and Coomassie blue staining revealed an easily visualized v-Mos band. However, less than 10% of p37 v-mos was in soluble form (62) . p37 v-mos immunoprecipitated from these extracts could also be phosphorylated by exogenously added PKA c (Fig. 3B) . The identity of the p37 v-mos band in recognition by anti-Mos antibody and its absence in control Sf9 insect cells. We found that the recombinant p37 v-mos immunoprecipitated from insect cells lacked autophosphorylation activity (62) . Furthermore, to totally eliminate the possibility of autophosphorylation in this experiment, immunoprecipitates were prepared with the kinase inhibitory antibody, anti-Mos(260-271) (52, 63) .
Inactivation of v-Mos kinase by PKA in vitro. It was not possible to determine the functional effect of in vitro PKA phosphorylation of the recombinant Mos protein, since the Mos protein was inactive to begin with. However, upon incubation with rabbit reticulocyte lysate, GST-Mos acquired the ability to autophosphorylate (Fig. 4A) . The recombinant Xenopus c-Mos protein fused to the maltose-binding protein is known to be activated in a similar fashion (38) . Importantly, the Mos autokinase activity was inhibited upon coincubation of GST-Mos and PKA c (compare lanes 2 and 5 in Fig. 4B ). PKA phosphorylation and autophosphorylation occurred in the same reaction. Therefore, to obtain an estimate of GST-Mos phosphorylation by PKA c , GST fused to the kinase-inactive H221Y mutant of v-Mos (58) was used as a control (Fig. 4B,  lane 3) . The kinase reaction shown in Fig. 4B , which would favor Mos phosphorylation by PKA at the expense of Mos autophosphorylation, which is reduced to about 50% (51) . This could explain the difference between the GST-Mos autophosphorylation results seen in Fig. 4A and B. Overall, GST-Mos phosphorylation in the presence of PKA was lowered to approximately the GST-Mos (H221Y) level (compare lanes 2 and 3 in Fig. 4B) . Significantly, the more slowly migrating species of GST-Mos, which typically result from v-Mos autophosphorylation (26, 32) , were present in dramatically reduced amounts upon PKA c coincubation. In this experiment, contaminating reticulocyte lysate kinase(s) also caused some phosphorylation of GST-Mos (e.g., Fig. 4B, lane 6) . Overall, these results strongly suggest that PKA caused nearly complete inhibition of v-Mos kinase in vitro, similar to the inhibition of v-Mos observed in vivo upon forskolin treatment.
Identification of the phosphorylation sites on p37 v-mos . To understand the mechanism of inhibition of v-Mos kinase by PKA, the phosphorylation sites were identified by tryptic phosphopeptide mapping and by site-directed mutagenesis. Initially, we compared the 2-D tryptic phosphopeptide maps of p37 v-mos phosphorylated in COS-1 cells in the absence and presence of coexpression of PKA c and p37
v-mos phosphorylated in vitro by PKA c (Fig. 5B to D) . It is evident that most of the in vivo phosphorylation of p37 v-mos was restricted to one phosphopeptide, marked no. 1. Phosphorylation on this peptide, as well as on some additional peptides (including peptides 2 and 3), increased upon coexpression of PKA c . Furthermore, trypsin digestion of in vitro-phosphorylated p37 v-mos also generated peptides 2 and 3. This result was confirmed by the observed comigration of the phosphopeptides 2 and 3 generated from the in vivo-and in vitro-labeled p37 v-mos . The minor phosphopeptide 4 resulted from in vitro phosphorylation of v-Mos by PKA. However, the PKA site included in this phosphopeptide, Ser-47, is not in the optimal sequence context for PKA, nor did its phosphorylation increase in vivo upon PKA c coexpression or forskolin treatment (compare Fig. 5B, C , and E). In fact, we have shown previously that Ser-47 may be phosphorylated in vivo by Cdc2 (6) . (Table 1 ). This result indicates that the length of peptide sequences surrounding the phosphorylatable residues was adequate for in vitro phosphorylation by PKA.
The predicted 2D tryptic map positions of all seven potential PKA phosphorylation sites on p37 v-mos are shown in Fig. 5A . This theoretical map was generated as described previously (9) and proved to be very useful as it provided the basis for further 2D mapping experiments involving comigration of trypsin-digested, in vitro-phosphorylated . The phosphopeptides were digested with trypsin and subjected to a 2-D chromatography run. Some of them were mixed with trypsin digests of in vitro PKA c -phosphorylated p37 v-mos and then analyzed by 2D mapping (9) . This type of analysis indicated that the major tryptic peptide, no. 1, is composed of v-Mos residues 54 to 63 in the sequence SCSIPLVAPR. The underlined S residue in this sequence is the phosphorylated serine 56, which is surrounded by 4) , GST-Mos (lanes 2 and 5), and kinase-inactive H221Y GST-Mos mutant (lanes 3 and 6) were subjected to an in vitro autophosphorylation reaction. For lanes 4 to 6, the recombinant proteins bound to glutathione beads were incubated with rabbit reticulocyte lysate (Promega, Madison, Wis.) for 30 min at 30ЊC and washed thoroughly five times with 20 mM N-2-hydroxyethylpiperazine-NЈ-2-ethanesulfonic acid (HEPES; pH 7.2)-150 mM NaCl-2 mM dithiothreitol-100 KIU of Trasylol per ml-1 mM sodium PP i . For lanes 1 to 3, the kinase reaction was performed with no prior incubation with the reticulocyte lysate. (B) Inhibition by PKA. After incubation with rabbit reticulocyte lysate and washing, the beads containing GST (lanes 1 and 4) , GST-Mos (lanes 2 and 5), and GST-Mos H221Y mutant (lanes 3 and 6) were subjected to the kinase phosphorylation reaction in the presence (lanes 1 to 3) or absence (lanes 4 to 6) of PKA c . Exposure times were 4 h for panel A and 2 h for panel B.
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on February 21, 2013 by PENN STATE UNIV http://mcb.asm.org/ the optimal sequence for PKA recognition. The experimentally observed position of this peptide also agrees with its position predicted by the amino acid composition and charge (Fig. 5A) . Figure 5E shows comigration of tryptic peptides containing Ser-263 phosphorylated in v-Mos in forskolin-treated cells and the synthetic peptide phosphorylated by PKA c in vitro.
Coexpression of PKA c in COS-1 cells resulted in increased phosphorylation at v-Mos residues Ser-56, Ser-102, and Ser-263, indicated as phosphopeptides 1, 2, and 3, respectively (Fig.  5C ). However, forskolin treatment, which resulted in the maximum (although transient) inhibition (Fig. 1) , correlated with increased in vivo phosphorylation at Ser-263 (Fig. 5E ). Comparison of relative intensities of the spots representing different phosphopeptides suggested that phosphorylation at Ser-263 may be responsible for v-Mos inhibition by PKA. On the basis of the peptide-mapping studies alone, the inhibitory role of Ser-56 phosphorylation could not be ruled out, since Ser-56 was phosphorylated under all conditions (Fig. 5) .
In vitro mutagenesis studies. To confirm the identity of the potential phosphorylation sites and determine their functional significance, serine residues 56, 102, and 263 were substituted by alanine. Ser-56 lies outside the kinase domain. Ser-102 lies near the conserved glycine-rich sequence present in protein kinases that is important for ATP binding (23) . Ser-263 lies between protein kinase subdomains VII and VIII, a region important for substrate recognition by the catalytic domain (Fig. 6A ). The 32 P in vivo-labeling experiment showed that phosphorylation of the S56A mutant, but not the other two mutants, was dramatically reduced when compared with that of wild-type v-Mos (Fig. 6B) Forskolin treatment did not affect the mobility of v-Mos or any of the mutants (Fig. 6A) . This is consistent with the interpretation derived from the peptide-mapping data that the forskolin treatment did not significantly increase the phosphorylation at Ser-56. The mutagenesis studies suggested that the phosphorylation at Ser-102 or Ser-263 may not result in altered mobility during SDS-PAGE. However, since only a small percentage of v-Mos is phosphorylated at these residues, this issue remains unresolved.
Various site-directed v-Mos mutants were also expressed as GST-Mos and purified from E. coli. All these were phosphorylated by PKA c in vitro (Fig. 3C) , and analysis of their tryptic peptide maps further supported our assignment of phosphorylation sites at Ser-56, Ser-102, and Ser-263. The spots 1, 2, and 3 were found missing in tryptic maps of S56A, S102A and S263A mutants respectively.
The significance of phosphorylation at the major phosphorylation site, Ser-56, was examined by determining the kinase activity of the S56A mutant in an in vitro autophosphorylation reaction. The results of one such experiment with stably transfected NIH 3T3 cells are shown in Fig. 7A ments, we observed a 25 to 50% decrease in v-Mos autokinase activity as a result of the S56A mutation. These results suggest that the phosphorylation at Ser-56 may have a stimulatory rather than inhibitory effect. However, they also suggest that Ser-56 phosphorylation is not essential for the protein kinase activity of p37 v-mos . The key substrate of v-Mos kinase in transformed cells is the mitogen-activated protein kinase/ERK kinase MEK (30, 36, 38, 42, 43, 50) . Therefore, we examined whether Ser-56 phosphorylation is necessary for MEK1 activation in stably transfected NIH 3T3 cells, which are often used for cellular transformation assays. MEK1 was immunoprecipitated from normally growing cells or after serum starvation for 24 h and subjected to autophosphorylation reaction (Fig. 7B) . In vitro autophosphorylation of the activated MEK1 correlates with its ability to phosphorylate mitogen-activated protein kinase (36, 42, 44) . The experimental results shown in Fig. 7B and C demonstrate that the ability of v-Mos to activate MEK1 was not affected by the S56A mutation.
Under conditions of normal growth, when an increase in the PKA activity was not forced, the S263A mutation also did not affect v-Mos kinase activity and its ability to activate MEK1 ( Fig. 7B and C ). Finally, we tested the ability of the alaninefor-serine substitutions to abrogate the forskolin-mediated inhibition of v-Mos kinase. The inhibitory effect of forskolin on v-Mos kinase was abrogated by the S263A mutation but not by the S56A or S102A mutation (Fig. 8A) . In this experiment, the magnitude of v-Mos kinase inhibition was somewhat smaller than the inhibition seen in the experiment illustrated in Fig. 1 . Nevertheless, this result is consistent with all the data presented above and strongly suggests that PKA inhibits v-Mos kinase via phosphorylation at Ser-263. Similar results were obtained when S263A mutant of v-Mos was assayed for its ability to phosphorylate GST-MEK1 (Fig. 8B ). Even though it is possible that forskolin treatment causes phosphorylation at additional sites, including Ser-102 (Fig. 5F ), this experiment suggests that phosphorylation at Ser-263 is responsible for forskolin inhibition of v-Mos kinase.
Autophosphorylation pattern of v-Mos and its mutants. In this study, we used mostly in vitro autophosphorylation as a measure of v-Mos activity, because it is the most sensitive assay and it correlates well with the transphosphorylation activity on an exogenously added substrate, e.g., vimentin (51, 53) . However, interpretation of the data would be difficult if autophosphorylation sites were also the PKA phosphorylation sites. To address this concern, tryptic phosphopeptide maps of in vitroautophosphorylated v-Mos and its mutants, S56A and S263A, were compared. All three maps are identical, ruling out the possibility that Ser-56 and Ser-263 are autophosphorylation sites (data not shown). Furthermore, examination of tryptic maps of in vivo-phosphorylated v-Mos under various conditions showed no evidence of increased phosphorylation at sites that are autophosphorylated in vitro.
Only a small fraction of p37 v-mos is active as protein kinase. v-mos migrated to the initial position characteristic of its hypophosphorylated form (data not shown). Considering the sensitivity of detection in this type of experiment, we believe that more than 90% of 35 S-labeled p37 v-mos stayed in the hypophosphorylated form after the kinase reaction and was therefore inactive. In a similar experiment, we previously found that most of the v-Mos produced by in vitro translation in rabbit reticulocyte lysate was also inactive (26) . Whether a large percentage of v-Mos is also inactive in vivo is a more difficult question. Thinking about it another way, the percentage of v-Mos protein that must be phosphorylated by PKA to achieve the inhibition of v-Mos kinase seen in our experiments is very small. Thus, the phosphorylation sites that are important for inhibition need not be seen as major phosphopeptides in our tryptic peptide analysis. In other words, if the inhibitory phosphorylation at Ser-263 is preferentially directed to the active v-Mos population, one might achieve a nearly complete inhibition of the v-Mos kinase, as observed in the experiments shown above (Fig. 1) .
DISCUSSION
Identification of the major v-Mos phosphorylation site. We have identified Ser-56 as the major in vivo phosphorylation site in v-Mos. This highlights a significant difference between the in vivo phosphorylation patterns of c-Mos xe and v-Mos. Freeman et al. (19) found that in c-Mos xe , Ser-3, the equivalent of Ser-34 in v-Mos, is the major in vivo phosphorylation site. Studies by Nishizawa et al. (37) further showed that the autophosphorylation at Ser-3 is essential for the stability of c-Mos in the egg.
Phosphorylation at Ser-3 is also important for the Mos interaction with MEK1 (12). Our results presented here indicate that Ser-34 is not a major in vivo phosphorylation site on v-Mos even though it may be autophosphorylated in vitro (5). Our results also indicate that Ser-56, which is the major phosphorylation site on v-Mos, is not phosphorylated by the autokinase reaction. So far, we have been unable to map phosphorylation sites on c-Mos because of low 32 P incorporation and the presence of other comigrating proteins during SDS-PAGE.
Although Ser-56 is evolutionarily conserved in c-Mos (45), its substitution by alanine did not affect the ability of v-Mos to autophosphorylate in vitro or activate MEK1 in vivo. Similarly, Ser-102, which may be a minor in vivo phosphorylation site, does not appear to be important for v-Mos enzyme activity. These results agree with those of a study by Freeman et al. (19) in which alanine-for-serine substitutions at positions corresponding to the v-Mos Ser-56 and Ser-102 in Xenopus c-Mos did not affect its ability to either induce oocyte maturation or function as the cytostatic factor.
Mechanism of PKA inhibition. In this study, we have shown that an increase in PKA activity results in the inhibition of v-Mos kinase activity in vivo. The inhibition was observed upon the activation of adenylate cyclase as a result of forskolin addition or upon overexpression of PKA c . Another activator of PKA, 8-bromo-cAMP, also inhibited v-Mos activity (data not shown). In our experiments, the inhibition manifested as a decrease in the extent of v-Mos autophosphorylation. The rate of phosphorylation is linear for only part of the duration of reaction (32) . Therefore, the rate of enzyme reaction (measured as the rate of phosphorylation in the early linear period of reaction) is most probably more inhibited than is apparent in Fig. 1 and 2 . The protein kinase activities of all the v-Mos proteins tested in these studies, e.g., P85
gag-mos and p37 v-mos encoded by 124 and HT1 strains of Mo-MuSV, were inhibited by PKA ( Fig. 1 and 2 and data not shown). Inhibition of p37
v-mos -HT1 may be significant because its sequence from residues 32 to 374 is identical to that of c-Mos (49) . Furthermore, the truncated v-Mos protein produced by the translational initiation at the second AUG, which is similar to c-Mos in structure and enzyme activity, was also inhibited by PKA to a similar degree to that of full-length v-Mos (62) .
In support of our results regarding v-Mos inhibition by PKA, both Mos and PKA are known to localize to microtubules, the latter through its regulatory subunit (reviewed in reference 34). Most significantly, we have identified the phosphorylation site responsible for the inhibition of v-Mos kinase by direct phosphorylation by PKA. In the present study, the phosphorylation at this site, Ser-263, increased significantly upon forskolin treatment. However, the site may still be phosphorylated only in a small percentage of v-Mos molecules. To explain this result, we propose that inhibitory phosphorylation may be specifically directed to the active population of v-Mos molecules.
Forskolin-induced inhibition of v-Mos is seen only upon short-term treatment. The lack of forskolin effect at later times may be due to attenuation or silencing of PKA activity, both of which are known to occur (4) . This would also explain why PKA c coexpression yields lower inhibition of v-Mos than forskolin treatment (compare Fig. 1 and 2) . The attenuation and silencing of the effects of PKA are achieved through a reduction in the level of its catalytic subunit and through dephosphorylation of PKA substrates by the increased phosphatase activity, which may colocalize with PKA through binding to a common anchoring protein (for reviews, see references 13 and 34). Of course, the differences in the subcellular localization of active PKA molecules that phosphorylate Mos under different experimental conditions may also contribute to the differences in the degree of inhibition. There is some evidence that PKA must compartmentalize with its substrates in order to function. The PKA-mediated inhibition of v-Mos may also be influenced by v-Mos phosphorylation at other sites. For example, in our study, the S263A mutant of v-Mos not only lacked the ability to be inhibited by forskolin treatment but also was modestly stimulated under these conditions (Fig. 8) . The inhibitory and stimulatory phosphorylations on v-Mos may be carried out by different isoforms of PKA in vivo. If this is true, the inhibitory and stimulatory phosphorylations being carried out by different isoforms of the same protein kinase would not be unique for Mos. As an example, the transcription factor cAMP-responsive element-binding protein (CREB) is phosphorylated by CaM kinase II at both Ser-133 and Ser-142. Ser-133 phosphosphorylation stimulates the CREB activity, while Ser-142 phosphorylation inhibits it (reviewed in reference 21). Interestingly, the CaM kinase IV phosphorylates only Ser-133 but not Ser-142. In the case of Mos, resolution of these issues will require further studies into the regulation of its kinase activity.
Surprisingly, the S263A mutation caused no increase in the v-Mos kinase activity in transfected cells. This result can be explained if one considers that the inhibitory effect of Ser-263 phosphorylation is completely reversed by another event such as a specific phosphorylation or dephosphorylation at another residue. The short-term forskolin treatment may tip the balance toward inhibition due to increased phosphorylation at Ser-263. Our result with the S263A v-Mos mutant is consistent with the observation by Freeman and Donoghue (17) that this mutation does not affect the focus-forming ability of v-Mos. However, as Freeman and Donoghue (17) also observed, the S358A mutation reduced the focus-forming ability of v-Mos to 58% of the control value, and the double mutant of v-Mos containing the S358A and S263A mutations had somewhat increased transforming activity (73% of the control value). Together, these results suggest that under certain conditions, the S263A mutation could cause an increase in v-Mos transforming activity.
The role of PKA phosphorylation at various sites other than Ser-263 remains to be understood. Of interest, the alanine-forserine substitution at residue 326, which is phosphorylated strongly by PKA in a v-Mos synthetic peptide (Table 1) , caused a dramatic reduction in v-Mos autokinase activity and transforming activity (17) . In that study, the S358A mutation also had an inhibitory effect, which synergized with the inhibition by the S326A mutation (17) . Further work is also needed to conclusively determine whether that Ser-263 is indeed phosphorylated by PKA or other protein kinases in vivo. It is well known that PKA interdigitates with various signaling pathways at multiple points (10, 22, 27, 31, 35) . Thus, it is possible that the differences in the effect of forskolin treatment for various times and also between forskolin treatment and PKA c coexpression are due to differences in the activation status of some of these pathways.
Vande Woude and colleagues have examined the mechanism of PKA inhibition of Mos-induced oocyte maturation in X. laevis (16, 31) . According to their studies, PKA does not influence Mos activity directly. Discrepancy between their data and ours may be due to species difference (Xenopus c-Mos versus v-Mos protein, which is similar to mouse c-Mos). In support of this interpretation, we note that Ser-263 is absent in Xenopus c-Mos (45) . Threonine at position 228 in Xenopus Mos, which is equivalent to residue 262 in v-Mos, is not a PKA consensus site. Inhibition by posttranslational regulation of Mos kinase activity may be more important in mice than in frogs (24, 63, 64) . Initiation of meiosis I requires new synthesis of Mos in Xenopus oocytes, but meiosis I can be completed in mouse oocytes without new synthesis of Mos (39) , presumably because of activation of already existing low levels of Mos protein (41, 63, 64) . We propose that Mos kinase is kept inactive in fully grown mouse oocytes by PKA. We believe that the prophase-arrested immature oocytes, with unusually high levels of PKA activity, may be more comparable to forskolintreated cells.
